Wedbush upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a neutral rating to an outperform rating in a report released on Friday morning, BenzingaRatingsTable reports. Wedbush currently has $21.00 price objective on the stock, up from their prior price objective of $20.00.
Several other research analysts have also recently issued reports on the stock. BidaskClub cut shares of Intellia Therapeutics from a hold rating to a sell rating in a report on Friday. Evercore ISI assumed coverage on shares of Intellia Therapeutics in a research note on Thursday, April 11th. They set an outperform rating for the company. Chardan Capital reissued a buy rating and set a $57.50 target price on shares of Intellia Therapeutics in a research note on Wednesday, February 27th. BTIG Research assumed coverage on shares of Intellia Therapeutics in a research note on Thursday, February 7th. They set a buy rating and a $20.00 target price for the company. Finally, Zacks Investment Research lowered shares of Intellia Therapeutics from a buy rating to a hold rating in a research note on Tuesday, January 29th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $29.25.
Intellia Therapeutics stock opened at $17.49 on Friday. The company has a market capitalization of $719.93 million, a PE ratio of -8.83 and a beta of 2.79. Intellia Therapeutics has a 12-month low of $11.03 and a 12-month high of $32.95.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. The business had revenue of $10.43 million during the quarter, compared to analysts’ expectations of $9.43 million. Intellia Therapeutics had a negative net margin of 257.28% and a negative return on equity of 31.42%. The business’s revenue was up 39.7% on a year-over-year basis. During the same period last year, the firm posted ($0.51) earnings per share. On average, analysts anticipate that Intellia Therapeutics will post -2.4 EPS for the current fiscal year.
In other Intellia Therapeutics news, EVP Andrew Schiermeier bought 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average cost of $15.72 per share, with a total value of $117,900.00. Following the completion of the purchase, the executive vice president now directly owns 3,250 shares in the company, valued at $51,090. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 4.10% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the stock. Nikko Asset Management Americas Inc. lifted its position in shares of Intellia Therapeutics by 20.0% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 5,980 shares of the company’s stock valued at $82,000 after acquiring an additional 995 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Intellia Therapeutics by 35.8% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 5,495 shares of the company’s stock valued at $75,000 after acquiring an additional 1,450 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Intellia Therapeutics by 6.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,983 shares of the company’s stock valued at $529,000 after acquiring an additional 1,936 shares in the last quarter. We Are One Seven LLC purchased a new stake in shares of Intellia Therapeutics in the 4th quarter valued at approximately $28,000. Finally, IHT Wealth Management LLC lifted its position in shares of Intellia Therapeutics by 28.4% in the 4th quarter. IHT Wealth Management LLC now owns 10,322 shares of the company’s stock valued at $141,000 after acquiring an additional 2,280 shares in the last quarter. Institutional investors and hedge funds own 71.65% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Featured Article: Cryptocurrencies
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.